[go: up one dir, main page]

DE69227627D1 - Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien - Google Patents

Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien

Info

Publication number
DE69227627D1
DE69227627D1 DE69227627T DE69227627T DE69227627D1 DE 69227627 D1 DE69227627 D1 DE 69227627D1 DE 69227627 T DE69227627 T DE 69227627T DE 69227627 T DE69227627 T DE 69227627T DE 69227627 D1 DE69227627 D1 DE 69227627D1
Authority
DE
Germany
Prior art keywords
pct
propargylamines
inhibitors
sec
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69227627T
Other languages
English (en)
Other versions
DE69227627T2 (de
Inventor
Peter Yu
Bruce Davis
Alan Boulton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Original Assignee
University of Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan filed Critical University of Saskatchewan
Publication of DE69227627D1 publication Critical patent/DE69227627D1/de
Application granted granted Critical
Publication of DE69227627T2 publication Critical patent/DE69227627T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/23Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton the carbon skeleton containing carbon-to-carbon triple bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69227627T 1991-03-01 1992-02-28 Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien Expired - Fee Related DE69227627T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/663,018 US5169868A (en) 1991-03-01 1991-03-01 Aliphatic propargylamines as specific mao-b inhibitors
PCT/CA1992/000090 WO1992015551A1 (en) 1991-03-01 1992-02-28 Aliphatic propargylamines as selective mao-b inhibitors and as neuroprotective agents

Publications (2)

Publication Number Publication Date
DE69227627D1 true DE69227627D1 (de) 1998-12-24
DE69227627T2 DE69227627T2 (de) 1999-06-24

Family

ID=24660178

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227627T Expired - Fee Related DE69227627T2 (de) 1991-03-01 1992-02-28 Alifatische Propargylamine als selektive MAO-B Inhibitoren und als Neuroprotektive Agenzien

Country Status (8)

Country Link
US (2) US5169868A (de)
EP (1) EP0573498B1 (de)
JP (1) JP3129733B2 (de)
AT (1) ATE173459T1 (de)
AU (1) AU658611B2 (de)
CA (1) CA2105171A1 (de)
DE (1) DE69227627T2 (de)
WO (1) WO1992015551A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5547995B1 (en) * 1993-05-04 1998-01-27 Sanofi Elf Use of selegiline in veterinary medicine
JP4782252B2 (ja) * 1994-01-10 2011-09-28 テバ ファーマシューティカル インダストリーズ リミテッド 1−アミノインダン及びこれらの組成物
DE19708461A1 (de) * 1997-02-18 1998-08-27 Meulen Volker Prof Dr Ter Verwendung aminerg wirkender Substanzen zur Herstellung eines Arzneimittels für die Behandlung viraler Infektionen des zentralen Nervensystems
US6111108A (en) * 1997-07-01 2000-08-29 Midwest Research Institute Extraction of biologically active components from Camptotheca acuminata with supercritical fluids
US5840979A (en) * 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
AU1956399A (en) * 1998-01-13 1999-08-02 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
US6809120B1 (en) 1998-01-13 2004-10-26 University Of Saskatchewan Technologies Inc. Composition containing propargylamine for enhancing cancer therapy
EA003677B1 (ru) * 1998-03-26 2003-08-28 Юниверсити Оф Саскачеван Текнолоджиз Инк. Алифатические аминокарбоновые и аминосульфоновые кислоты, аминонитрилы и аминотетразолы как агенты сохранения клеток
US6984754B1 (en) 1998-03-26 2006-01-10 University Of Saskatchewan Technologies Inc. Aliphatic amino carboxylic and amino phosphonic acids amino nitriles and amino tetrazoles as cellular rescue agents
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US20040062787A1 (en) * 2001-12-17 2004-04-01 Daley William Lionel Therapeutic combination of amlodipineand benazepril/benazeprilat
EP1565185A4 (de) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation Neuroprotektive eisenchelatoren und pharmazeutische zusammensetzungen damit
EP1686973A4 (de) 2003-11-25 2009-03-25 Technion Res & Dev Foundation Zusammensetzungen und verfahren zur behandlung von kardiovaskulären erkrankungen und krankheiten
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
EP2053033A1 (de) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Verbindungen zur Verwendung bei der Abbildung, Diagnose und/oder Behandlung von Erkrankungen des zentralen Nervensystems oder von Tumoren
EP2309858A4 (de) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
WO2010121719A1 (en) * 2009-04-23 2010-10-28 Bayer Schering Pharma Aktiengesellschaft Novel precursor molecules for f-18 labelled pet tracers
HUE044221T2 (hu) 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
WO2012050971A2 (en) * 2010-09-29 2012-04-19 Teva Pharmaceutical Industries Ltd. Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB342651A (en) * 1929-10-03 1931-02-03 British Celanese Improvements in the manufacture of artificial filaments, threads & the like by wet spinning methods
GB842651A (en) * 1957-04-01 1960-07-27 Lakeside Lab Inc Novel acetylene compounds and process of preparing same
BE576562A (fr) * 1958-03-21 1959-07-01 Armour & Co Solution stabilisée de chymotrypsine
US3000903A (en) * 1959-09-15 1961-09-19 Lakeside Lab Inc Phenylalkylhydrazines and use as psychotherapeutics
US2997442A (en) * 1960-03-30 1961-08-22 Louise F Peale Lubricating oil composition
FR1453844A (fr) * 1965-03-19 1966-07-22 Soc Ind Fab Antibiotiques Sifa Nouvelles n-propynyl alcoylamines et leurs sels et procédé de préparation
US4201725A (en) * 1974-05-20 1980-05-06 Labaz Secondary amines
US4650907A (en) * 1985-12-05 1987-03-17 Merrell Dow Pharmaceuticals Inc. Nonaromatic fluoroallylamine MAO inhibitors
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材

Also Published As

Publication number Publication date
US5169868A (en) 1992-12-08
CA2105171A1 (en) 1992-09-02
JP3129733B2 (ja) 2001-01-31
WO1992015551A1 (en) 1992-09-17
JPH06505241A (ja) 1994-06-16
ATE173459T1 (de) 1998-12-15
US5508311A (en) 1996-04-16
AU1323692A (en) 1992-10-06
EP0573498A1 (de) 1993-12-15
DE69227627T2 (de) 1999-06-24
AU658611B2 (en) 1995-04-27
EP0573498B1 (de) 1998-11-18

Similar Documents

Publication Publication Date Title
ATE173459T1 (de) Alifatische propargylamine als selektive mao-b inhibitoren und als neuroprotektive agenzien
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
ES2141137T3 (es) Agentes terapeuticos para la enfermedad de parkinson.
NO308739B1 (no) Imidazolderivater samt medisinsk sammensetning og anti-HIV- sammensetning omfattende samme
DK1424330T3 (da) Aktivator for peroxisom proliferator-responsiv receptor delta
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
ES2062558T3 (es) Compuestos contra el cancer.
KR920014810A (ko) 항균제
DK0607193T3 (da) Antifugale triazolderivater
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
PT1468692E (pt) Utilizacao de 2,6-dialquil-4-sililfenois para o tratamento do xantoma
ES2127762T3 (es) Quinoleinas 2-sustituidas para el tratamiento de las leismaniosis.
HU911992D0 (en) 2-(amino-alkyl)-5-(aryl-alkyl)-1,3-dioxanes, and process for the production of the medical preparations containing them
IT1196423B (it) Benzotiazolin-composti
EP0753511A4 (de) Indol-derivate und diese enthaltende arzneimittel
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
SE8303913L (sv) Heterocykliska foreningar
ES2190781T3 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
DK0609281T3 (da) Benzoxazol-, benzothiazol- og benzimidazol-derivater til anvendelse som fungicider
PT100682A (pt) Agentes anti-helminticos derivados de benzimidazole e processo para a sua preparacao
ES2140393T3 (es) Compuestos de penem.
DE69521895D1 (de) Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten
KR880005088A (ko) 제초활성을 갖는 1-카바모일-2-피라졸린 유도체
DK0395527T3 (da) Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee